Mehalick David 4
4 · Coeptis Therapeutics Holdings, Inc. · Filed Jan 9, 2024
Insider Transaction Report
Form 4
Mehalick David
DirectorCEO and President10% Owner
Transactions
- Purchase
Common Stock
2024-01-05$0.69/sh+5,050$3,484→ 2,762,611 total - Purchase
Common Stock
2024-01-08$0.67/sh+6,000$4,020→ 2,768,611 total - Purchase
Common Stock
2024-01-08$0.66/sh+14,004$9,243→ 2,782,615 total
Footnotes (1)
- [F1]Includes 156,250 shares of common stock that are issuable upon exercise of options that are or will become exercisable in the next 60 days. exercise of options that are or will become exercisable in the next 60 days.